Molecular pathways in aseptic loosening of orthopaedic endoprosthesis;Molekulare signalwege der aseptischen endoprothesenlockerung

Biomedizinische Technik

Volumn 53, Issue 3, 2008, Pages 93-103

  Drees, Philipp ^a   Eckardt, Anke ^b   Gay, Renate E ^c   Gay, Steffen ^c   Huber, Lars C ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Department of Orthopedic and Trauma Surgery   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Implant failure; Osteolysis; Particle; Polyethylene; Wear

Indexed keywords

COST EFFECTIVENESS; PARTICLES (PARTICULATE MATTER); POLYETHYLENES; WEAR OF MATERIALS;

ACTIVATED MACROPHAGES; IMPLANT FAILURES; MOLECULAR MECHANISM; MOLECULAR PATHWAYS; OPERATION PROCEDURE; ORTHOPAEDIC IMPLANTS; OSTEOLYSIS; PROSTHETIC LOOSENING;

JOINT PROSTHESES;

ENDOPROSTHESIS; IMPLANT; INFECTION; OSTEOLYSIS; PROSTHESIS LOOSENING; REVIEW;

EID: 44949182026     PISSN: 00135585     EISSN: None     Source Type: Journal    
DOI: 10.1515/BMT.2008.021     Document Type: Review

References (73)

1. Astrand J, Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 2004; 22: 244-249.
2. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein G. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001; 166: 2705-2711.
3. Barrack RL, Castro FP Jr, Szuszczewicz ES, Schmalzried TP. Analysis of retrieved uncemented porous-coated acetabular components in patients with and without pelvic osteolysis. Orthopedics 2002; 25: 1373-1378; discussion 1378.
4. Bauer TW. Particles and periimplant bone resorption. Clin Orthop Relat Res 2002; 138-143.
5. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1: 11-21.
6. Bobyn JD, Pilliar RM, Cameron HU, Weatherly GC. The optimum pore size for the fixation of porous-surfaced metal implants by the ingrowth of bone. Clin Orthop Relat Res 1980; 263-270.
7. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Bone 2002; 31: 582-590.
8. Bund. Gesundheitsberichterstattung des Bundes. 2006; 37-39.
9. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-538.
10. Campbell P, Shen FW, McKellop H. Biologic and tribologic considerations of alternative bearing surfaces. Clin Orthop Relat Res 2004; 98-111.
11. Corisdeo S, Gyda M, Zaidi M, Moonga BS, Troen BR. New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem Biophys Res Commun 2001; 285: 335-339.
12. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002; 109(Suppl): S67-S79.
13. Crotti TN, Smith MD, Findlay DM, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004; 25: 565-573.
14. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002; 115: 4317-4325.
15. Dean DD, Schwartz Z, Blanchard CR, et al. Ultrahigh molecular weight polyethylene particles have direct effects on proliferation, differentiation, and local factor production of MG63 osteoblast-like cells. J Orthop Res 1999; 17: 9-17.
16. DeLaSalle H, Benghuzzi H, Deville R, Tucci M. The effects of PMMA particle number on MG-63 osteoblast cell function. Biomed Sci Instrum 2006; 42: 48-53.
17. Dossing DA, Stern PH. Receptor activator of NF-kappaB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol. J Cell Biochem 2005; 95: 1029-1041.
18. Fender D, Harper WM, Gregg PJ. The trent regional arthroplasty study. Experiences with a hip register. J Bone Joint Surg Br 2000; 82: 944-947.
19. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10: 1165-1177.
20. Granchi D, Amato I, Battistelli L, et al. Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. Biomaterials 2005; 26: 2371-2379.
21. Green TR, Fisher J, Stone M, Wroblewski BM, Ingham E. Polyethylene particles of a 'critical size' are necessary for the induction of cytokines by macrophages in vitro. Biomaterials 1998; 19: 2297-2302.
22. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, Nalepka JL, Seabold JM. Does endotoxin contribute to aseptic loosening of orthopedic implants? J Biomed Mater Res B Appl Biomater 2005; 72: 179-185.
23. Hallab NJ, Anderson S, Stafford T, Glant T, Jacobs JJ. Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res 2005 Mar; 23: 384-391.
24. Hansen T, Otto M, Buchhorn GH, et al. New aspects in the histological examination of polyethylene wear particles in failed total joint replacements. Acta Histochem 2002; 104: 263-269.
25. Ikeda F, Nishimura R, Matsubara T, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114: 475-484.
26. Ingham E, Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005; 26: 1271-1286.
27. Kavanagh BF, Wallrichs S, Dewitz M, et al. Charnley low-friction arthroplasty of the hip. Twenty-year results with cement. J Arthroplasty 1994; 9: 229-234.
28. Kenner L, Hoebertz A, Beil T, et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol 2004; 164: 613-623.
29. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 2003; 89: 771-777.
30. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-286.
31. Kobayashi N, Kadono Y, Naito A, et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. Embo J 2001; 20: 1271-1280.
32. Landgraeber S, Toetsch M, Wedemeyer C, et al. Overexpression of p53/BAK in aseptic loosening after total hip replacement. Biomaterials 2006; 27: 3010-3020. Epub 2006 Jan 30.
33. Lappalainen R, Santavirta SS. Potential of coatings in total hip replacement. Clin Orthop Relat Res 2005; 72-79.
34. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97: 1566-1571.
35. Liebau C, Pap G. [Early implantation of a knee endoprosthesis in young rheumatic patients?]. Z Orthop Ihre Grenzgeb 1997; 135: Oa9-Oa10.
36. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13: 1015-1024.
37. MacQuarrie RA, Fang Chen Y, Coles C, Anderson GI. Wear-particle-induced osteoclast osteolysis: the role of particulates and mechanical strain. J Biomed Mater Res B Appl Biomater 2004; 69: 104-112.
38. Matsumoto M, Kogawa M, Wada S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004; 279: 45969-45979.
39. Matsuo K, Galson DL, Zhao C, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004; 279: 26475-26480.
40. McKellop HA. Bearing surfaces in total hip replacements: state of the art and future developments. Instr Course Lect 2001; 50: 165-179.
41. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999; 154: 203-210.
42. Morawietz L, Classen RA, Schroder JH, et al. Proposal for a histopathological consensus classification of the periprosthetic interface membrane. J Clin Pathol 2006; 59: 591-597.
43. Nagasawa T, Kobayashi H, Kiji M, et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002; 130: 338-344.
44. Neale SD, Sabokbar A, Howie DW, Murray DW, Athanasou NA. Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption. J Orthop Res 1999; 17: 686-694.
45. Orishimo KF, Claus AM, Sychterz CJ, Engh CA. Relationship between polyethylene wear and osteolysis in hips with a second-generation porous-coated cementless cup after seven years of follow-up. J Bone Joint Surg Am 2003; 85-A: 1095-1099.
46. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-15676.
47. Pap T, Claus A, Ohtsu S, et al. Osteoclast-independent bone resorption by fibroblast-like cells. Arthritis Res Ther 2003; 5: R163-R173.
48. Pilliar RM, Lee JM, Maniatopoulos C. Observations on the effect of movement on bone ingrowth into porous-surfaced implants. Clin Orthop Relat Res 1986; 108-113.
49. Pollice PF, Rosier RN, Looney RJ, Puzas JE, Schwarz EM, O'Keefe RJ. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am 2001; 83-A: 1057-1061.
50. Sabokbar A, Kudo O, Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 2003; 21: 73-80.
51. Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC. Osteoprotegerin and inflammation. Eur Cytokine Netw 2002; 13: 144-153.
52. Saleh KJ, Celebrezze M, Kassim R, et al. Functional outcome after revision hip arthroplasty: a metaanalysis. Clin Orthop Relat Res 2003; 254-264.
53. Schlesinger PH, Mattsson JP, Blair HC. Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation. Miner Electrolyte Metab 1994; 20: 31-39.
54. Schmalzried TP, Akizuki KH, Fedenko AN, Mirra J. The role of access of joint fluid to bone in periarticular osteolysis. A report of four cases. J Bone Joint Surg Am 1997; 79: 447-452.
55. Schwarz EM, Looney RJ, O'Keefe RJ. Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2000; 2: 165-168.
56. Stanley ER, Berg KL, Einstein DB, et al. Biology and action of colony - stimulating factor-1. Mol Reprod Dev 1997; 46: 4-10.
57. Streicher RM, Thomsen M. [Polyethylene as an implant material]. Orthopäde 2003; 32: 23-31.
58. Sychterz CJ, Engh CA Jr, Swope SW, McNulty DE, Engh CA. Analysis of prosthetic femoral heads retrieved at autopsy. Clin Orthop Relat Res 1999; 223-234.
59. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005.
60. Taki N, Tatro JM, Nalepka JL, et al. Polyethylene and titanium particles induce osteolysis by similar, lymphocyte-independent, mechanisms. J Orthop Res 2005; 23: 376-383.
61. Tanabe N, Maeno M, Suzuki N, et al. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Life Sci 2005; 77: 615-626.
62. Thirunavukkarasu K, Halladay DL, Miles RR, Geringer CD, Onyia JE. Analysis of regulator of G-protein signaling-2 (RGS-2) expression and function in osteoblastic cells. J Cell Biochem 2002; 85: 837-850.
63. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004; 350: 735-736.
64. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003; 100: 125-130.
65. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 1998; 41: 1987-1994.
66. von Knoch F, Heckelei A, Wedemeyer C, et al. Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. J Biomed Mater Res A 2005; 75: 288-294.
67. Wedemeyer C, von Knoch F, Pingsmann A, et al. Stimulation of bone formation by zoledronic acid in particle-induced osteolysis. Biomaterials 2005; 26: 3719-3725.
68. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282-290.
69. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AWJr, Ahmed-Ansari A, Sell KW, Pollard JW, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 1990; 87: 4828-4832.
70. Wilkinson JM, Hamer AJ, Stockley I, Eastell R. Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. J Orthop Res 2005; 23: 520-525.
71. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 1998; 273: 28355-28359.
72. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345: 442-444.
73. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003; 18: 599-609.